https://www.ema.europa.eu/en/medicines/human/EPAR/welireg 2025 false false false Netherlands French English treatment outcome syndication feed summary of product characteristics package leaflet drug evaluation drug approval europe administration, oral belzutifan belzutifan belzutifan antineoplastic agents antineoplastic agents HIF-2alpha Inhibitor HIF-2alpha Inhibitor risk management product surveillance, postmarketing clear cell renal cell carcinoma Advanced Clear Cell Renal Cell Carcinoma Refractory Clear Cell Renal Cell Carcinoma adult von Hippel-Lindau disease Central Nervous System Hemangioblastoma carcinoma, renal cell Pancreatic Neuroendocrine Tumor Unresectable Pancreatic Neuroendocrine Tumor EPAS1 protein, human aged drug interactions pregnancy breast feeding drug evaluation, preclinical
--- https://www.cadth.ca/fr/belzutifan 2023 false false false Canada French English drug evaluation canada belzutifan belzutifan von Hippel-Lindau disease